Published: 19 October 2022
Author(s): Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, Marta Arbrile, Alice Barinotti, Elena Rubini, Alessandro Morotti, Vittorio Pengo, Dario Roccatello, Savino Sciascia
Issue: January 2023
Section: Review Article

Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis (arterial, venous, and microvascular) and/or pregnancy morbidity occurring in subjects persistently positive for antiphospholipid antibodies (aPL). Current laboratory classification criteria for APS include the presence of lupus anticoagulant (LA), anticardiolipin (aCL), or anti-β2-glycoprotein I antibodies (aß2GPI) tested positive on two separate occasions at least 12 weeks apart [1]. While the APS classification criteria are being currently updated to improve homogeneity in clinical research [2], patients who seek medical treatment often have a variety of laboratory and/or clinical characteristics that may not completely encompass the classification criteria for overt APS.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.